Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.54 |
| ▸ | TACR2 | P21452 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1443525 | 0.86 | FDPS (0.54) | ALDH1A1HPGDMEN1POLBKMT2A | |
| SCHEMBL29958206 | 0.86 | ALDH1A1 (0.65) | ALDH1A1HPGDMEN1POLBKMT2A | |
| SCHEMBL1121313 | 0.86 | ALDH1A1 (0.65) | ALDH1A1HPGDMEN1POLBKMT2A | |
| SCHEMBL20489952 | 0.85 | FDPS (0.54) | ALDH1A1HPGDMEN1POLBKMT2A | |
| SCHEMBL10291447 | 0.85 | FDPS (0.53) | ALDH1A1HPGDMEN1POLBKMT2A | |
| SCHEMBL18733594 | 0.84 | ALDH1A1 (0.51) | ALDH1A1HPGDMEN1POLBKMT2A | |
| SCHEMBL30159697 | 0.83 | ALDH1A1 (0.73) | ALDH1A1HPGDKMT2ATACR2TDP1 | |
| SCHEMBL493684 | 0.83 | ALDH1A1 (0.73) | ALDH1A1HPGDKMT2ATACR2TDP1 | |
| SCHEMBL2610707 | 0.83 | ALDH1A1 (0.56) | ALDH1A1HPGDMEN1POLBKMT2A | |
| SCHEMBL30209172 | 0.82 | THRA (0.51) | ALDH1A1HPGDMEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619097-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2024107434-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11685725-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685725-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| CN-116251081-A | 3-arylindenone compounds and pharmaceutical uses thereof | 复旦大学 | 2023-06-13 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20210363128-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-11-25 | — | — | US | disclosed |
| WO-2019178401-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| US-9394272-B2 | 1,3-dioxane compound having fluorine atom in axial position, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-07-19 | — | — | US | disclosed |
| US-20150368225-A1 | 1,3-DIOXANE COMPOUND HAVING FLUORINE ATOM IN AXIAL POSITION, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-12-24 | — | — | US | disclosed |
| WO-2004026305-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| CN-1449368-A | Method of producing fluorinated and chlorinated benzaldehydes and compositions thereof | MILLIKEN & CO (US) | 2003-10-15 | — | — | CN | disclosed |
| US-20030176481-A1 | Novel imidazole derivatives with anti-inflammatory activity | J. URIACH & CIA S.A. (ES) | 2003-09-18 | — | — | US | disclosed |
| EP-1313691-A2 | FLUORINATED AND CHLORINATED BENZALDEHYDES | Milliken & Company (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1313690-A1 | METHOD OF PRODUCING FLUORINATED AND CHLORINATED BENZALDEHYDES AND COMPOSITIONS THEREOF | Milliken & Company (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1270559-A1 | NOVEL IMIDAZOLE DERIVATIVES WITH ANTI-INFLAMMATORY ACTIVITY | J. URIACH & CIA. S.A. (ES) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002020452-A2 | NOVEL FLUORINATED AND CHLORINATED BENZALDEHYDES | MILLIKEN & COMPANY (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002020447-A1 | METHOD OF PRODUCING FLUORINATED AND CHLORINATED BENZALDEHYDES AND COMPOSITIONS THEREOF | MILLIKEN & COMPANY (US) | 2002-03-14 | — | — | WO | disclosed |
| US-6300525-B1 | CONTACTING SUBSTITUTED BENZENE IN CARBON MONOXIDE ATMOSPHERE HAVING SPECIFIED PRESSURE IN PRESENCE OF METAL HALIDE AND HYDROHALIC ACID CATALYST AND AT SPECIFIED TEMPERATURE | MILLIKEN & COMPANY | 2001-10-09 | — | — | US | disclosed |
| US-6297405-B1 | EFFICIENTLY PRODUCED BENZALDEHYDE CHEMICAL INTERMEDIATE SUBSTITUTED BY ONE HALOGEN AND ALKYL OR CYCLOALKYL GROUPS AT OTHER POSITIONS | MILLIKEN & COMPANY | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685725-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | YAP1, YES1, MYC | ALDH1A1 3176/4885HPGD 4716/4885MEN1 3614/4885 |
| US-20030176481-A1 | Novel imidazole derivatives with anti-inflammatory activity | IL1B, IL1A, MIF | ALDH1A1 394/4885HPGD 94/4885MEN1 4771/4885 |
| US-20210363128-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | YAP1, MYC, YES1 | ALDH1A1 3004/4885HPGD 4719/4885MEN1 3627/4885 |
| US-20150368225-A1 | 1,3-DIOXANE COMPOUND HAVING FLUORINE ATOM IN AXIAL POSITION, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CXCR1, HAX1, RCC1 | ALDH1A1 1040/4885HPGD 4652/4885MEN1 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.